From: Oral health-related quality of life in 4–16-year-olds with and without juvenile idiopathic arthritis
ECOHIS total score > 0 | Child-OIDP SC score > 0 | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Unadjusted regressions | Adjusted regressionsa | Unadjusted regressions | Adjusted regressionsa | |||||||||||
n | OR | 95% CI | p-value | OR | 95% CI | p-value | n | OR | 95% CI | p-value | OR | 95% CI | p-value | |
JIA category | ||||||||||||||
Oligoarthritis persistent | 32 | Ref | Ref | 44 | Ref | Ref | ||||||||
Not oligoarthritis persistentb | 45* | 3.64 | (1.09–12.08) | 0.035 | 3.32 | (0.82–13.40) | 0.092 | 62** | 6.32 | (1.99–20.01) | 0.002 | 6.29 | (1.83–21.63) | 0.004 |
Age at JIA onset | ||||||||||||||
≤ 6 years | 64 | Ref | Ref | 46 | Ref | Ref | ||||||||
> 6 years | 32 | 0.82 | (0.29–2.36) | 0.719 | 0.61 | (0.17–2.11) | 0.430 | 79 | 1.03 | (0.45–2.35) | 0.952 | 1.52 | (0.56–4.14) | 0.414 |
Disease duration | ||||||||||||||
≤ 5 years | 57 | Ref | Ref | 60 | Ref | Ref | ||||||||
> 5 years | 39 | 3.13 | (0.94–10.34) | 0.062 | 2.81 | (0.77–10.27) | 0.117 | 65 | 0.97 | (0.44–2.17) | 0.948 | 0.87 | (0.34–2.19) | 0.762 |
Steroids, ever used | ||||||||||||||
No steroids ever used | 74 | Ref | Ref | 99 | Ref | Ref | ||||||||
Steroids ever used | 22 | 0.79 | (0.25–2.53) | 0.696 | 0.57 | (0.15–2.14) | 0.409 | 26 | 1.32 | (0.51–3.41) | 0.572 | 2.32 | (0.79–6.88) | 0.128 |
DMARDs, ongoing | ||||||||||||||
No sDMARDs nor bDMARDs ongoing | 26 | Ref | Ref | 49 | Ref | Ref | ||||||||
sDMARDs, but no bDMARDs ongoing | 34 | 2.04 | (0.64–6.55) | 0.230 | 2.00 | (0.57–7.02) | 0.280 | 27 | 2.68 | (0.95–7.58) | 0.063 | 1.38 | (0.41–4.65) | 0.601 |
bDMARDs ongoingc | 36 | 5.82 | (1.38–24.56) | 0.016 | 7.59 | (1.77–32.67) | 0.006 | 49 | 1.27 | (0.49–3.29) | 0.630 | 1.20 | (0.40–3.62) | 0.743 |
DMARDs, ever used | ||||||||||||||
No sDMARDs nor bDMARDs ever used | 15 | Ref | Ref | 37 | Ref | Ref | ||||||||
sDMARDs, but no bDMARDs ever used | 43 | 2.52 | (0.70–9.01) | 0.155 | 3.41 | (0.91–12.79) | 0.069 | 38 | 2.50 | (0.87–7.21) | 0.090 | 1.20 | (0.37–3.82) | 0.764 |
bDMARDs ever usedc | 38 | 5.67 | (1.30–24.66) | 0.021 | 9.20 | (1.93–43.97) | 0.005 | 50 | 1.35 | (0.47–3.88) | 0.573 | 1.15 | (0.35–3.72) | 0.822 |
Disease statusd | ||||||||||||||
Inactive disease/remission on/off medication | 59 | Ref | Ref | 74 | Ref | Ref | ||||||||
Continued activity/flare | 37 | 2.81 | (0.85–9.32) | 0.091 | 2.65 | (0.81–8.65) | 0.106 | 51 | 3.62 | (1.57–8.34) | 0.003 | 3.01 | (1.15–7.89) | 0.025 |
MDgloVAS | ||||||||||||||
VAS = 0 | 63 | Ref | Ref | 79 | Ref | Ref | ||||||||
VAS > 0 | 33 | 2.27 | (0.68–7.54) | 0.182 | 2.29 | (0.71–7.44) | 0.168 | 46 | 2.74 | (1.21–6.23) | 0.016 | 1.98 | (0.77–5.08) | 0.156 |
VAS pain | ||||||||||||||
VAS = 0 | 36 | Ref | Ref | 45 | Ref | Ref | ||||||||
VAS > 0 | 60 | 1.27 | (0.46–3.56) | 0.646 | 1.13 | (0.38–3.42) | 0.825 | 76 | 4.16 | (1.46–11.86) | 0.008 | 4.39 | (1.20–16.14) | 0.026 |
PRgloVAS | ||||||||||||||
VAS = 0 | 25 | Ref | Ref | 34 | Ref | Ref | ||||||||
VAS > 0 | 71 | 1.91 | (0.65–5.61) | 0.238 | 1.69 | (0.52–5.50) | 0.386 | 87 | 3.38 | (1.08–10.58) | 0.037 | 2.54 | (0.65–9.97) | 0.182 |
CHAQe | ||||||||||||||
CHAQ = 0 | 37 | Ref | Ref | 54 | Ref | Ref | ||||||||
CHAQ > 0 | 59 | 1.58 | (0.57–4.36) | 0.382 | 1.76 | (0.58–5.37) | 0.322 | 71 | 6.38 | (2.26–18.06) | < 0.001 | 4.21 | (1.40–12.68) | 0.011 |
Dental caries | ||||||||||||||
d1-5ft/D1-5FTf = 0 | 65 | Ref | Ref | 54 | Ref | Ref | ||||||||
d1-5ft/D1-5FTf > 0 | 29 | 2.60 | (0.69–9.87) | 0.160 | 1.97 | (0.49–7.97) | 0.342 | 68 | 2.04 | (0.84–4.96) | 0.117 | 1.63 | (0.57–4.65) | 0.362 |